Dashboard

Amicus Therapeutics, Inc. (FOLD)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

B

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

B

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

CEO

John Francis Crowley

Employees

584

Industry

Endocrinology and Metabolism Biopharmaceuticals

Sector

Healthcare

Headquarters

Cranbury

Exchange

NASDAQ

Summary Stats

Market Cap

2.22B

Revenue

318M

Net Income

-270M

EPS

-$0.97

Price-to-Earnings

-8.13

Price-to-Book

9.29

Debt-to-Equity

2.47

News

Analyst Ratings

Price targets projected by 10 analysts

High

$31.00

Average

$23.20

Low

$19.00

Ratings calculated by 10 analysts

Buy

8

Hold

2

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Missed by -$0.05

Actual

-$0.30 -20.0%

Consensus

-0.25

Report Date

Year Ago

-0.25

Year Ago Change %

Down 20%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites